QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:AUTL

Autolus Therapeutics - AUTL Stock Forecast, Price & News

$2.15
+0.16 (+8.04%)
(As of 01/31/2023 05:32 PM ET)
Add
Compare
Today's Range
$1.96
$2.15
50-Day Range
$1.74
$3.25
52-Week Range
$1.60
$5.04
Volume
1.26 million shs
Average Volume
532,955 shs
Market Capitalization
$372.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Autolus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
338.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Autolus Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.70) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

61st out of 1,055 stocks

Biological Products, Except Diagnostic Industry

13th out of 170 stocks


AUTL stock logo

About Autolus Therapeutics (NASDAQ:AUTL) Stock

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Stock News Headlines

Autolus Therapeutics announces Board changes
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Why Autolus Therapeutics Stock Is Crashing Today
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Syncona: Autolus' FELIX Trial Of Obe-cel Meets Primary Endpoint
Autolus Therapeutics Prices Public Offering Of 75 Mln ADSs
Mizuho Securities Keeps Their Buy Rating on Autolus Therapeutics (AUTL)
Autolus Therapeutics: Q3 Earnings Insights
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
324
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+318.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-142,100,000.00
Pretax Margin
-6,969.80%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$3.45 per share

Miscellaneous

Free Float
128,583,000
Market Cap
$372.08 million
Optionable
Not Optionable
Beta
1.57

Key Executives

  • Christian Martin Itin
    Chief Executive Officer & Director
  • Christopher Vann
    Chief Operating Officer & Senior Vice President
  • Lucinda Crabtree
    Chief Financial Officer
  • Martin Pulé
    Chief Scientific Officer & Senior Vice President
  • David Brochu
    Chief Technical Officer & Senior Vice President













AUTL Stock - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price forecast for 2023?

3 brokers have issued 1 year target prices for Autolus Therapeutics' stock. Their AUTL share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2023?

Autolus Therapeutics' stock was trading at $1.90 at the beginning of 2023. Since then, AUTL shares have increased by 5.8% and is now trading at $2.01.
View the best growth stocks for 2023 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 500,400 shares, a decline of 24.3% from the December 31st total of 661,000 shares. Based on an average trading volume of 560,400 shares, the days-to-cover ratio is currently 0.9 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) issued its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. The business had revenue of $2.37 million for the quarter, compared to analysts' expectations of $0.30 million.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Pendal Group Ltd (1.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $2.01.

How much money does Autolus Therapeutics make?

Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $347.85 million and generates $2.33 million in revenue each year. The company earns $-142,100,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

The company employs 324 workers across the globe.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.

This page (NASDAQ:AUTL) was last updated on 1/31/2023 by MarketBeat.com Staff